Combination antifungal therapy: From bench to bedside

Baldeep Wirk, John R. Wingard

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Invasive fungal infections are major causes of mortality in immunocompromised patients. Despite improved outcomes with new antifungals, there remains a pressing need to further improve outcomes, especially with invasive aspergillosis and other invasive mold infections. Combination antifungal therapy is an attractive option that offers the prospect for improved efficacy, decreased toxicity, reduced likelihood for the emergence of resistance, and shorter courses of therapy. The current available evidence regarding the role of combination antifungal therapy for invasive fungal infections is discussed in this article, including data from in vitro studies, animal models, and human clinical trials to try to clarify this important issue. Randomized, prospective clinical trials are urgently needed, especially for invasive aspergillosis.

Original languageEnglish (US)
Pages (from-to)466-472
Number of pages7
JournalCurrent Infectious Disease Reports
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Aspergillosis
Immunocompromised Host
Fungi
Therapeutics
Randomized Controlled Trials
Animal Models
Clinical Trials
Mortality
Infection
Invasive Fungal Infections
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

@article{0bf3f0dfcff34204b1278b2f6c35037f,
title = "Combination antifungal therapy: From bench to bedside",
abstract = "Invasive fungal infections are major causes of mortality in immunocompromised patients. Despite improved outcomes with new antifungals, there remains a pressing need to further improve outcomes, especially with invasive aspergillosis and other invasive mold infections. Combination antifungal therapy is an attractive option that offers the prospect for improved efficacy, decreased toxicity, reduced likelihood for the emergence of resistance, and shorter courses of therapy. The current available evidence regarding the role of combination antifungal therapy for invasive fungal infections is discussed in this article, including data from in vitro studies, animal models, and human clinical trials to try to clarify this important issue. Randomized, prospective clinical trials are urgently needed, especially for invasive aspergillosis.",
author = "Baldeep Wirk and Wingard, {John R.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1007/s11908-008-0076-x",
language = "English (US)",
volume = "10",
pages = "466--472",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "6",

}

Combination antifungal therapy : From bench to bedside. / Wirk, Baldeep; Wingard, John R.

In: Current Infectious Disease Reports, Vol. 10, No. 6, 01.12.2008, p. 466-472.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Combination antifungal therapy

T2 - From bench to bedside

AU - Wirk, Baldeep

AU - Wingard, John R.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Invasive fungal infections are major causes of mortality in immunocompromised patients. Despite improved outcomes with new antifungals, there remains a pressing need to further improve outcomes, especially with invasive aspergillosis and other invasive mold infections. Combination antifungal therapy is an attractive option that offers the prospect for improved efficacy, decreased toxicity, reduced likelihood for the emergence of resistance, and shorter courses of therapy. The current available evidence regarding the role of combination antifungal therapy for invasive fungal infections is discussed in this article, including data from in vitro studies, animal models, and human clinical trials to try to clarify this important issue. Randomized, prospective clinical trials are urgently needed, especially for invasive aspergillosis.

AB - Invasive fungal infections are major causes of mortality in immunocompromised patients. Despite improved outcomes with new antifungals, there remains a pressing need to further improve outcomes, especially with invasive aspergillosis and other invasive mold infections. Combination antifungal therapy is an attractive option that offers the prospect for improved efficacy, decreased toxicity, reduced likelihood for the emergence of resistance, and shorter courses of therapy. The current available evidence regarding the role of combination antifungal therapy for invasive fungal infections is discussed in this article, including data from in vitro studies, animal models, and human clinical trials to try to clarify this important issue. Randomized, prospective clinical trials are urgently needed, especially for invasive aspergillosis.

UR - http://www.scopus.com/inward/record.url?scp=63249131372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249131372&partnerID=8YFLogxK

U2 - 10.1007/s11908-008-0076-x

DO - 10.1007/s11908-008-0076-x

M3 - Review article

C2 - 18945387

AN - SCOPUS:63249131372

VL - 10

SP - 466

EP - 472

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 6

ER -